The COVID-19 pandemic has changed routine care practice for older persons, especially in those with frailty living in long term care (LTC) facilities. Due to the high mortality rates of Nursing home (NH) residents during the first wave of the COVID-19 pandemic, priority for COVID-19 vaccinations was given to this vulnerable population. However, the safety and efficacy of such vaccines in older frail elders remains questionable due to the fact that initial randomized clinical trials (RCTs) for such vaccines did not include this population. This type of discrimination in patient participation in RCTs continues and has been recognized in the literature. Nevertheless, in the context of a worldwide emergency, COVID-19 vaccination in older persons living in LTC facilities may provide a solid basis to protect against negative outcomes, such as COVID-19 infection and death. In this report, we present the protocol of the GeroCovid Vax study, an Italian study that began in February 2021 which is aimed at investigating the safety and efficacy of the anti-SARS-CoV-2 vaccinations in older persons living in LTCs. This protocol specially aims to continuously and closely monitor events related to- and following- the anti-SARS-CoV-2 vaccination in elderly living in LTC facilities. In this report, we will provide information related to the study protocol and describe baseline characteristics of the sample.

Abbatecola, A., Incalzi, R., Malara, A., Palmieri, A., Di Lonardo, A., Fedeli, G., et al. (2022). Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study. VACCINE, 40(15), 2324-2330 [10.1016/j.vaccine.2022.02.064].

Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study

Bellelli G.;
2022

Abstract

The COVID-19 pandemic has changed routine care practice for older persons, especially in those with frailty living in long term care (LTC) facilities. Due to the high mortality rates of Nursing home (NH) residents during the first wave of the COVID-19 pandemic, priority for COVID-19 vaccinations was given to this vulnerable population. However, the safety and efficacy of such vaccines in older frail elders remains questionable due to the fact that initial randomized clinical trials (RCTs) for such vaccines did not include this population. This type of discrimination in patient participation in RCTs continues and has been recognized in the literature. Nevertheless, in the context of a worldwide emergency, COVID-19 vaccination in older persons living in LTC facilities may provide a solid basis to protect against negative outcomes, such as COVID-19 infection and death. In this report, we present the protocol of the GeroCovid Vax study, an Italian study that began in February 2021 which is aimed at investigating the safety and efficacy of the anti-SARS-CoV-2 vaccinations in older persons living in LTCs. This protocol specially aims to continuously and closely monitor events related to- and following- the anti-SARS-CoV-2 vaccination in elderly living in LTC facilities. In this report, we will provide information related to the study protocol and describe baseline characteristics of the sample.
Articolo in rivista - Articolo scientifico
COVID-19 vaccine; Elderly; Frailty syndrome; GeroCovid Vax; Long term care (LTC); Nursing homes (NH); Safety;
English
2324
2330
7
Abbatecola, A., Incalzi, R., Malara, A., Palmieri, A., Di Lonardo, A., Fedeli, G., et al. (2022). Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study. VACCINE, 40(15), 2324-2330 [10.1016/j.vaccine.2022.02.064].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/360427
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
Social impact